Zydus Cadila said on Friday that it has received final approval from the US health regulator to market Droxidopa capsules, used to treat low blood pressure.
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Droxidopa capsules in the strength of 100 mg, 200 mg, and 300 mg, Cadila Healthcare said in a regulatory filing.
Zydus Cadila is part of the Cadila Healthcare group.
Zydus Cadila has more orders for Covid-19 vaccine than it can make: Report
312 approvals
Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a light-headed feeling.
The company further said that Droxidopa is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).
Zydus Cadila gets USFDA nod to market cream for treating skin conditions
The newly approved medication will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 312 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.
Shares of Cadila Healthcare were trading 1.51 per cent lower at ₹460.45 apiece on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.